Interrater reliability of the Psychiatric Research Interview for Substance and Mental Disorders in an HIV-infected cohort: experience of the National NeuroAIDS Tissue Consortium

The interrater reliability of the Psychiatric Research Interview for Substance and Mental Disorders (PRISM) was assessed in a multicentre study. Four sites of the National NeuroAIDS Tissue Consortium performed blinded reratings of audiotaped PRISM interviews of 63 HIV‐infected patients. Diagnostic m...

Full description

Saved in:
Bibliographic Details
Published in:International journal of methods in psychiatric research 2006-01, Vol.15 (3), p.131-138
Main Authors: Morgello, S., Holzer III, C.E., Ryan, E., Young, C., Naseer, M., Castellon, S.A., Frol, A.B., Atkinson, J. Hampton, Gelman, B.B., Grant, I., Singer, E.J.
Format: Article
Language:English
Subjects:
Adult
Aged
Cannabis
Comorbidity
Depressive Disorder, Major - chemically induced
Depressive Disorder, Major - diagnosis
Diagnosis, Dual (Psychiatry)
Female
Health Surveys
HIV
HIV Infections - physiopathology
HIV Infections - psychology
Human immunodeficiency virus
Humans
interrater reliability
Interview, Psychological
Male
Middle Aged
Observer Variation
PRISM
Psychiatry - methods
Substance-Related Disorders - classification
Substance-Related Disorders - diagnosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The interrater reliability of the Psychiatric Research Interview for Substance and Mental Disorders (PRISM) was assessed in a multicentre study. Four sites of the National NeuroAIDS Tissue Consortium performed blinded reratings of audiotaped PRISM interviews of 63 HIV‐infected patients. Diagnostic modules for substance‐use disorders and major depression were evaluated. Seventy‐six per cent of the patient sample displayed one or more substance‐use disorder diagnoses and 54% had major depression. Kappa coefficients for lifetime histories of substance abuse or dependence (cocaine, opiates, alcohol, cannabis, sedative, stimulant, hallucinogen) and major depression ranged from 0.66 to 1.00. Overall the PRISM was reliable in assessing both past and current disorders except for current cannabis disorders when patients had concomitant cannabinoid prescriptions for medical therapy. The reliability of substance‐induced depression was poor to fair although there was a low prevalence of this diagnosis in our group. We conclude that the PRISM yields reliable diagnoses in a multicentre study of substance‐experienced, HIV‐infected individuals. Copyright © 2006 John Wiley & Sons, Ltd.
ISSN:1049-8931
1557-0657
DOI:10.1002/mpr.189